Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.


2014 International Conference and Scientific Sessions - Abstracts

These abstract were presented at the 11th International PH Conference and Scientific Sessions held in Indianapolis, Indiana, June 22-24, 2014. 


PHA congratulates the winners of the awards for best abstracts in basic and clinical science:

Basic Science 

1. Resistin-like Molecule Proteins Promote Pulmonary Vascular Endothelial Activation and Apoptosis: Cross talk Between Vascular Endothelial and Smooth Muscle Cell

2. Non-Biased Proteomics Discovery of PAH Biomarkers Periostin and Matrix Matalloproteinase 9

Clinical Science 

3. Right Ventriclo-Arterial Coupling in Patients with PAH Undergoing Rapid Dose Escalation of Treprostinil

4. Trends in Pediatric Inpatient Sildenafil Use in the United States, 2004-2013 


Databases and Registries

5. Pulmonary Hypertension Mortality Surveillance – United States, 2001-2010 

Mehanistic Studies

6. BMPR2 Silencing Activates ERK1/2-AP1 Signaling Through Upstream Effects of RAF 

7. Systems-level Regulartion of microRNA Networks by miR-130/301 Promotes PH

8. Exercise Training Ameliorates RV Cardiomyocyte ‘Glycolytic Switch’ and Improves Aerobic Capacity In Rats with Hypoxic Pulmonary Hypertension

9. Boosting Right Ventricular (RV) Autophagy with Rapamycin is Insufficient to Attenuate RV Dysfunction, Despite Favorable Effects on RV Afterload

10. Spironolactone Suppresses NF-kappaB and AP-1 Inflammatory Signaling Independent of the Meralocortoid Receptor

11. The Effect of Endogenous Sex Hormones on Hemodynamics, Exercise Capacity and Right Ventricular (RV) Pro-Apoptotic Signaling in Su5416/hypoxia-induced Pulmonary Hypertension (SuHx-PH) 

12. Neonatal Hyperoxic Lung Injury Alters Adult Rght Ventricular Remodeling Responses to Hypoxia Exposure in Rats 

13. Effects of AMBRISENTAN, Daursentan, Bosentan, and Sitaxsentan on Human Hepatic Uptake and EFFLUX TRANSPORTERS

14. Selective Pharmacologic Inhibition of Class IIa Histone Deacetylases Rescues Experimental PAH

15. Ambrisentan and Tadalafil Synergistically Relax Endothelin-Induced Contraction of Rat Pulmonary Arteries

16. Regulation of MicroRNA Expression in the Lungs by Exposure to Air Pollution & Antigen 

17. PK10453, a Non-Selective PDGF Receptor Inhibitor, Prevents the Progression of PAH

18. Non-Biased Proteomics Discovery of Pulmonary Artery Hypertension Biomarkers Periostin and Matrix Metalloproteinase 9

19. VE-Cadherin Downregulation May be a Feature of Endothelial Transdifferentiation in Monocrotaline-induced Pulmonary Hypertension 

20. Resistin-Like Molecule Proteins Promote Pulmonary Vascular Endothelial Activation and Apoptosis: Cross Talk Between Vascular Endothelial and Smooth Muscle Cells

Therapeutic Stategies

21. A Phase 1 Study of CTX-4430, A Potential New Oral Treatment for Pulmonary Arterial Hypertension 


Associated Diseases and Conditions

22. Pulmonary Hypertension in Advanced Cystic Fibrosis: Pulmonary Vasodilator Therapy Prior to Lung Transplantation

23. Reversible Pulmonary Hypertension in Multiple Myeloma

24. Reversal of Pulmonary Hypertension in a patient with Down’s syndrome, Obstructive Sleep Apnea and repaired Tetralogy of Fallot

25. Successful Orthotopic Liver Transplantation in a Patient with Portopulmonary Hypertension Treated with Tadalafil and Perioperative Nitric Oxid

26. Pulmonary Arterial Hypertension in Patients with Congenital Heart Disease and Heterotaxy/Polysplenia Syndrome

Diagnosis, Screening, and Assessment

27. A Case of Vascular Rings Presenting as Chronic Cough

28. PAH Diagnosis During Pregnancy and Management: A 6 Year Follow-up

29. Multiple Peripheral Pulmonary Artery Stenoses and Moyamoya Disease: a Possible Novel Pulmonary and Systemic Arteriopathy Mimicking PAH

30. Calcific Atherosclerosis of the Pulmonary Artery in Long-Standing PAH 

31. Transudative Chylothorax in the Setting of Acute Right Heart Failure in a Patient with Pulmonary Arterial Hypertension (PAH): A Case Report


32. Management of a Child with Severe Pulmonary Hypertension Presenting with Severe Systemic Hypertension: A Case Study

Therapeutic Strategies

33. Imatinib For Treatment Of Pulmonary Hypertension Associated With Gaucher Disease 

34. Acute Improvement in RV Function with the Initiation and Rapid Titration of IV Treprostinil in Combination with Oral Tadalafil

35. Rapid Transition Between Intravenous and Subcutaneous Treprostinil Infusions

36. Successful Surgical Repair of Multiple Anomalous Pulmonary Venous Returns and Vasodilator Treatment Leading to Substantial Improvement of Pulmonary Hypertension 

37. Palliative Care Does Not Mean Stopping PAH Medication; A Case Study in Optimal Care Coordination

38. Pulmonary Arterial Hypertension in a Patient with β-thalassemia Intermedia and Reversal with Infusion Epoprostenol then Transition to Oral Calcium Channel Blocker Therapy 


39. First Pulmonary Endarterectomy in Latvia

40. Recurrent Episodes of Intussusception After Initiation of Intravenous Epoprostenol



Associated Disease and Conditions

41. Does the Severity of Portopulmonary Hypertension (POPH) Matter in the Intensive Care Unit (ICU) Post Liver Transplant

42. Intravenous Prostacylin Therapy in Pulmonary Hypertension

43. Autoimmune Disease-Associated PAH Versus Idiopathic PAH: Which Subset of Patients Receives More Combination Therapy? 

44. Clinical Characteristics and Outcomes in Veterans with Combined Pulmonary Fibrosis and Emphysema (CPFEE) with and without Concomitant Pulmonary Hypertension

45. Pulmonary Hypertension in the Setting of Hereditary Hemorrhagic Telangiectasia

46. Evaluation of the Relationship Between Inflammatory Factors (IL6, TNFa, HS.Crp) and Secondary Pulmonary Hypertension in Patients with COPD: A Cross Sectional Study

Databases and Registries 

47. Outcomes of Pulmonary Hypertension (PH) Patients Admitted to a University Hospital MICU 

48. National Biological Sample and Data Repository for Pulmonary Arterial Hypertension 

49. Prognostic Value of Renal Function in Patients With Pulmonary Arterial Hypertension (PAH) Treated With Epo-A in the PROSPECT Registry

50. The OPsumit USers (OPUS) Registry: A US-Based, Observational Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice

51. Characteristics of Idiopathic Pulmonary Arterial Hypertension (IPAH) and PAH Associated With Connective Tissue Disease (APAH-CTD) Patients in PROSPECT 

52. The PROSPECT Resigtry of PAH: Description of Patients who Transitioned from Inhaled Prostacyclin to Intravenous Epoprosentol 

53. Demographics, Disease Characteristics, and Outcomes of Patients With Non-Group 1 Pulmonary Hypertension (PH) Enrolled in the PROSPECT Registry

54. Development of a PAH Quality Assessment Program 

Diagnostic Screening and Assement

55. Acute Vasodilator Challenge Testing In Patients With Heart Failure With Preserved Ejection Fraction

56. Relationship Of NYHA Functional Class to Hemodynamics And Survival In Heart Failure With Preserved Ejection Fraction 

57. Trends in Right Heart Catheterizations in a Small Community Hospital

58. The Minimal Important Difference in the Borg Dyspnea Score for Patients with Pulmonary Arterial Hypertension 

59. Identifying Right Ventricular Dysfunction after Negative Computerized Tomographic Pulmonary Angiograph

60. Assessing Knowledge and Confidence Levels of Nurses Caring for the Pediatric Pulmonary Hypertension Patient

61. Effect of Six-Minute Walk Test on Pro-BNP Levels in Patients with Pulmonary Arterial Hypertension&

Mechanistic Studies

62. Phosphodiesterase Type 5 Inhibitors Improve Right Ventricular Function and Pulmonary Compliance in Patients with Pulmonary Hypertension 

63. Right Ventriclo-Arterial Coupling in Patients with PAH Undergoing Rapid Dose Escalation of Treprostini


64. Premature Infants with PH: Does the Presence of a Cardiac Shunt Affect Morbidity and Mortality?

65. Sildenafil Use in an Infant Population: A Retrospective Review

66. Serum B-Type Natriuretic Peptide as a Predictor of Pulmonary Hypertension in Premature Infants with Bronchopulmonary Dysplasia 

67. Trends in Pediatric Inpatient Sildenafil Use in the United States, 2004-2013 

Quality of Life

68. Impact of Riociguat on Health-Related Quality of Life in Patients with CTEPH

69. Impact of Riociguat on Health-Related Quality of Life in Patients with PAH

70. Dyspnea, Depression and Health Related Quality of Life [HRQoL] in Patients with Pulmonary Arterial hypertension

71. PAH has a Global Impact on Patients & Caregivers: Results from US Population Based Qualitative Interviews and Quantitative Surveys

72. Prevalence of Psychological Issues among Patients with Pulmonary Hypertension

Therapeutic Strategies

73. Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects 

74. Safety and Tolerability of Transitioning from Parenteral Treprostinil to Oral Treprostinil in Patients with Pulmonary Arterial Hypertension 

75. Inhaled Temperature-Stable Epoprostenol Is Equivalent to Inhaled Nitric Oxide in Post-Cardiac Surgery Patients with Pulmonary Hypertension

76. Budget Cuts? Managing the Pulmonary Arterial Hypertension Medication Formulary While Being Cost Conscious for Your Institution 

77. Safety of Outpatient Initiation of Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension

78. Long-term Survival of Patients with PH Treated with Different Iloprost and Sildenafil Combination Regimens 

79. Comparative Efficacy and Tolerability of 13 Drugs in PAH: A Systematic Review and Network Meta-Analysis 

80. Pharmacokinetics and Pharmacodynamics of the Selective Prostacyclin Receptor Agonist Selexipag

81. Assessment of Gas Exchange in Patients with Severe Pulmonary Hypertension Related to Pulmonary Fibrosis, Before and During Treatment with Parenteral Prostanoid 

82. Ambrisentan Therapy in Patiens with PAH Receing Concomitant Sildenafil Therapy: An Analysis of the ARIES-3 Study

83. Change in 6MWD as a Predictor of Survival of PAH: Minimal Clinically Important Difference (MID) and Beyond

84. ATHENA-1: Long Term Clinical Improvements Following the Addition of Ambrisentatn to Background PDE5i Therapy in Patients with PAH

85. Transitioning Patients With Pulmonary Arterial Hypertension From Parenteral Prostacyclin: Single-Center Experience

86. An Open-Label Extension Trial of UT-15C SR in Subjects with Pulmonary Arterial Hypertension

87. Recognition and Clinical Outcomes of Tunneled Interatrial Shunts Among Patients With Pulmonary Hypertension


88. Macitentan Improves Cardiopulmonary Hemodynamics (HD) in Patients with PAH: Results from the Randomized SERAPHIN Trial

89. Riociguat for the Treatment of PAH: 1-year Results from the PATENT-2 Long-Term Extension Study

90. Riociguat for the Treatment of CTEPH: 1-year results from the CHEST-2 Long-Term Extension Study

91. Ambrisentan for the Treatment of PAH: Results of the Ambrisentan in PAH, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

92. Frequency of Death Without Parenteral Prostaglandin Therapy in Pulmonary Arterial Hypertension Patients at a Tertiary Referral Center

93. Long-Term Hemodynamic Improvements in PH with Ambrisentatn Therapy

94. Health Outcome Assessment in Patients with PAH Treated with Riociguat: 1-Year Results from the PATENT-2 Long-Term Extension Study

95. Post-Marketing Hepatic Safety Profile of Ambrisentan in Patients with PAH

96. Evaluating Health Outcomes in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension...

97. Ambrisentan Therepy in Patients with PAH: 3-Year Outcome

98. Long-Term Ambrisentan Therapy for PAH: Comparison Etiology

99. Long-Term Ambrisentan Therapy in Patients with PAH: An Analysis by WHO Functional Class

2014 Conference

















  Sign in to add a review